AML1-ETO is generated from t(8;21)(q22;q22), which is a common form of chromosomal translocation associated with development of acute myeloid leukemia (AML). Although full-length AML1-ETO alone fails to promote leukemia because of its detrimental effects on cell proliferation, an alternatively spliced isoform, AML1-ETO9a, without its C-terminal NHR3/NHR4 domains, strongly induces leukemia. However, full-length AML1-ETO is a major form of fusion product in many t(8;21) AML patients, suggesting additional molecular mechanisms of t(8;21)-related leukemogenesis. Here, we report that disruption of the zinc-chelating structure in the NHR4 domain of AML1-ETO by replacing only one critical amino acid leads to rapid onset of leukemia, demonstrating that the NHR4 domain with the intact structure generates inhibitory effects on leukemogenesis. C hromosomal translocation is one of the most common genetic abnormalities in acute myeloid leukemia (AML) (1). AML1-ETO is a fusion protein transcription factor generated from t(8;21)(q22;q22). This translocation is identified in Ͼ10% of all cases and up to 40% of the French-American-British M2 subtype of AML (2-5). However, expression of AML1-ETO by itself fails to cause leukemia (6-11), which suggests the requirement of ''additional hits'' for AML1-ETO-positive cells to become leukemogenic.
C
hromosomal translocation is one of the most common genetic abnormalities in acute myeloid leukemia (AML) (1) . AML1-ETO is a fusion protein transcription factor generated from t(8;21)(q22;q22). This translocation is identified in Ͼ10% of all cases and up to 40% of the French-American-British M2 subtype of AML (2) (3) (4) (5) . However, expression of AML1-ETO by itself fails to cause leukemia (6) (7) (8) (9) (10) (11) , which suggests the requirement of ''additional hits'' for AML1-ETO-positive cells to become leukemogenic.
Previously, our group reported that the C-terminally truncated form of AML1-ETO (AML1-ETOtr) is strongly leukemogenic (12) . Interestingly, a short form of AML1-ETO, AML1-ETO9a, which is produced by alternative splicing, was identified in t(8;21) leukemia patient samples, and expression of AML1-ETO9a induced rapid leukemia development in mice (13) . AML1-ETOtr and AML1-ETO9a encode 556 and 575 aa (a.a.), respectively, and both lack the NHR3 and NHR4 regions. These results suggest that the N-terminal portion of ETO (NHR1 and NHR2) fused with AML1, is sufficient to cause leukemia. In addition, the C-terminal domains of AML1-ETO (NHR3 and NHR4) may actually play a role in suppressing disease development.
In this report, we demonstrate that the zinc (Zn)-chelating structure of the NHR4 is responsible for generating inhibitory effects on leukemia development, and that this region interacts with SON, a potential DNA/RNA-binding protein, to cause growth arrest in AML1-ETO-expressing cells. Furthermore, we demonstrate a crucial role of SON in cell proliferation, and abnormal localization of SON in AML1-ETO-expressing leukemia patient samples.
Results

Deletion or Disruption of the Zn-Chelating Structure of the NHR4
Domain of AML1-ETO Leads to leukemogenesis. The NHR4 domain of AML1-ETO contains two Zn-chelating motifs including cysteines 663, 666, 674, 677, 683, 687, 699, and histidine 695 (Fig. 1B ) (14) . To investigate the role of the NHR4 domain in AML1-ETOmediated leukemogenesis, we performed transplantation experiments using murine hematopoietic cells infected with the retroviral vector MigR1 containing full-length AML1-ETO (MigR1-AE), an NHR4-deleted form of AML1-ETO (MigR1-AE-⌬NHR4), or AML1-ETO with a single amino acid mutation at one of the zinc-chelating residues, cysteine 663 (MigR1-AE-C663S) (Fig. 1 A) . The point mutation C663S has been shown to disrupt the Znchelating structure (14, 15) . As expected, expression of AML1-ETO alone (MigR1-AE) did not induce leukemogenesis. However, MigR1-AE-⌬NHR4 and MigR1-AE-C663S rapidly induced leukemia (Fig. 1C) . Western blot analysis of spleen extracts from the leukemic mice showed the expression of AE-⌬NHR4 and AE-C663S in splenocytes [supporting information (SI) Fig. S1 A] . Analysis of hematopoietic cells from mice transplanted with AE-⌬NHR4 showed the presence of myeloid blasts in blood, bone marrow, and spleen (Fig. S1B) . Histological examination revealed extensive infiltrations of leukemic cells in the spleen and the liver from the AE-⌬NHR4 leukemic mice (Fig. S1C) . Flow-cytometrric analysis of peripheral blood from leukemic mice with AE-⌬NHR4 showed that EGFP ϩ cells are negative for lymphoid and myeloid differentiation markers, such as CD3, B220, CD11b, and Gr-1. The proportion of c-Kit ϩ cells was greatly increased in the EGFP ϩ population, indicating the AE-⌬NHR4 protein causes an increase in immature myeloid progenitor-like cells (Fig. 1D) . AE-C663S leukemic mice showed the similar phenotypes (data SON by immunofluorescence microscopy. First, we examined the localization of endogenous SON. SON localized within the nuclei in a speckled distribution, excluded from the DAPI-stained DNArich region (Fig. S4) . These results are consistent with previous reports showing localization of SON at the nuclear speckles, called interchromatin granule clusters (21) . To determine whether SON colocalizes with AML1-ETO, HA-tagged AML1-ETO was transfected in HeLa cells and the cells were immunostained with HA antibody and SON antibody. We detected colocalization of endogenous SON and HA-tagged AML1-ETO (Fig. 2D) , although not all AML1-ETO colocalized with SON. In addition, SON was found to colocalize with the transfected ETO protein (Fig. 2D) .
ETO-C663S Mutation Eliminates SON Interaction, but Not N-CoR In-
teraction. Because the NHR4 domain of ETO has been known to interact with N-CoR/SMRT, we tested whether the cysteine 663 mutant is also defective in N-CoR binding. SON N-terminal fragment (a.a. 1-81) and the N-CoR fragment containing RIII domain (a.a. 975-1250) were transfected with wt-ETO or ETO-C663S. The PPPLIP sequence present in the RIII domain of N-CoR has been reported to interact with the region encompassing NHR3 and NHR4 of ETO (14, 22) . However, it had not been clearly demonstrated whether NHR4 alone interacts with RIII domain of N-CoR in mammalian cells. Interestingly, ETO-C663S completely lost its interaction with the SON fragment, while retaining its ability to interact with the N-CoR RIII domain (Fig. 3A) .
To compare the effect of NHR4 mutation on interactions with full-length SON and full-length N-CoR, wild-type ETO, ETO-C663S, and ETO-⌬NHR4 were expressed in 293T cells, and the SON antibody or N-CoR antibody was used for immunoprecipitation. Both SON and wild-type ETO was detected in the complex precipitated with SON antibody (Fig. 3B) . However, neither ETO- C663 nor ETO-⌬NHR4 was significantly detected in the immunoprecipitates (Fig. 3B ). In contrast, N-CoR interaction was not affected by deletion or C663S mutation in the NHR4 region of ETO (Fig. 3B) . It is likely that N-CoR interaction is still mediated by other domains of ETO whereas SON interaction absolutely requires Zn-chelating topology of ETO.
Knock-Down of SON by siRNA Induces Significant Growth Arrest in the
Cells. It has been demonstrated that full-length AML1-ETO fails to induce leukemia (6-11), possibly because of AML1-ETO-induced growth arrest and cell death (23) . This observation suggests that the preleukemic AML1-ETO-positive cells need to overcome these cell cycle and apoptotic defects to realize their leukemogenic potential. We found that deletion or mutations of NHR4 promotes leukemogenic ability of AML1-ETO, indicating that disruption of the interaction between AML1-ETO and proteins that interact with NHR4 alleviate the hindrance to leukemogenesis. Therefore, we hypothesize that the interaction of SON with NHR4 of AML1-ETO may cause growth arrest. (Fig. 4C) , HeLa, and BJ primary fibroblasts (data not shown). Significant morphological changes, such as elongation of K562 cells, were also observed after introducing SON siRNA (Fig. 4D) . As knock-down of SON alone was able to induce growth arrest, we could not test the specific effect of disrupting the interaction of SON with AML1-ETO. However, these results indicate that SON is essential for normal cell growth, and knock-down of SON results in impaired cell proliferation that is also observed in cells with AML1-ETO expression.
Expression of the SON N-Terminal Fragment Rescues AML1-ETO-
Induced Growth Arrest. Knock-down of SON by siRNA alone causes growth arrest. Therefore, we chose another approach to block the interaction between AML1-ETO and SON. Since the N-terminal region of SON corresponding to a.a. 1-81 was sufficient to interact with NHR4 of AML1-ETO (Fig. 2B) , we overexpressed the N-terminal fragment of SON to interfere with the interaction between AML1-ETO and endogenous SON. To ensure the proper nuclear localization, we expressed the first 140 a.a. of SON (SON-140) that has a putative nuclear localization signal at a.a. 117-128 (based on a GenBank search). Immunostaining revealed that SON-140 perfectly colocalized with endogenous SON (Fig. 5A) . Expression of this SON-140 fragment efficiently inhibited the interaction between AML1-ETO and endogenous SON (Fig. 5B) .
To test whether expression of the SON N-terminal fragment could overcome AML1-ET-induced growth arrest, U937 cells with inducible AML1-ETO expression (23) were infected with MigR1 (control vector) or MigR1-Flag-SON-140. In the presence of tetracycline (without AML1 (Fig. 5C ), confirming that, unlike SON siRNA, SON-140 itself does not affect cell growth. Then we cultured these two populations in the absence of tetracycline to induce AML1-ETO expression. As reported previously, induction of AML1-ETO in the MigR1 control line caused growth arrest. The Flag-SON-140-expressing line also underwent growth arrest during the first 2-3 days after tetracycline removal when the induced AML1-ETO expression exceeded SON-140 expression (Fig. S5) . However, unlike MigR1 control cells, these cells started to expand after days 4-5, when AML1-ETO induction is at a moderate level (Fig. S5) , and recovered a normal growth rate (Fig.  5C ). These results demonstrate that inhibition of the interaction between AML1-ETO and endogenous SON can rescue cells from AML1-ETO-induced growth arrest, suggesting that AML1-ETO and SON interaction generates negative effects on cell growth. 8;21) and the level of SON mRNA (data not shown). Then we analyzed cellular localization of the SON protein in these cell lines by immunostaining using SON antibody. In addition to the nuclear SON, cytoplasmic localization of SON was detected in t(8;21)-positive cell lines, Kasumi-1 and SKNO-1, whereas SON was perfectly localized within the nucleus in non-t(8;21) leukemic cells K562 and U937 (Fig. 6A) . Quantification of density of SON staining from image analysis revealed that cytoplasmic SON accounts for 33 Ϯ 6% and 29 Ϯ 5% of the total SON protein in Kasumi-1 and SKNO-1 cells, respectively. However, expression of AML1-ETO in other hematopoietic cells, K562 and U937, did not cause cytoplasmic export of SON (data not shown), suggesting that t(8;21) AML cells, such as Kasumi-1 and SKNO-1, may have acquired abnormalities in SON localization, so that they overcome the growth arrest effect generated by the interaction between SON and AML1-ETO.
Next we analyzed SON localization in primary AML cells from patients. Leukemic blasts from the blood of non-t(8;21) AML patients and t(8;21) AML patients were collected and immunostained with SON antibody. Strikingly, t(8;21) AML cells showed remarkable cytoplasmic localization of SON (Fig. 6B) , which is even more obvious than that observed in t(8;21)-positive cell lines. Approximately 55 Ϯ 7% of the total amount of SON was located in the cytoplasm, based on image analysis. In contrast, non-t(8;21) AML cells did not show any SON proteins present in the cytoplasm (Fig. 6B) . These results strongly suggest that abnormal cytoplasmic localization of SON is involved in t(8;21)-associated AML.
Discussion
Although the abnormal fusion protein AML1-ETO generated by t(8;21) is necessary to cause leukemia, this fusion protein alone has failed to cause leukemia (6) (7) (8) (9) (10) (11) , indicating the secondary mutation may cooperate with AML1-ETO for leukemogenesis. Here we demonstrated that the NHR4 domain of AML1-ETO with the intact Zn-chelating structure generates growth inhibitory effects to suppress leukemia development. Furthermore, SON is identified as an NHR4-interacting protein that regulates AML1-ETOassociated growth arrest. Although SON was shown to be ubiquitously expressed (18) and evolutionarily conserved (24) , its functions are largely unknown. In the early 1990s, Chumakov et al. reported that expression of a SON fragment corresponding to a.a.1267-2409 of human full-length SON in transformed NIH 3T3 cells inhibited tumorigenesis, suggesting that SON may have antioncogenic potential (25) . In contrast, the 1940-2256 a.a. fragment has been shown to inhibit Bax-mediated apoptosis in yeast (26) . Because, in both experiments, only partial fragments of SON were expressed, we cannot rule out the possibility that some expressed proteins may dominantly inhibit the function of the endogenous full-length SON protein, rather than revealing the authentic function of SON. However, these data strongly suggest that SON is involved in cell proliferation and/or apoptosis, which regulate tumorigenesis. In this study, we demonstrated that knock-down of endogenous SON by siRNA leads to growth arrest of cells, indicating that SON is an indispensable factor for cell proliferation. We have observed that SON knockdown causes cell cycle arrest and subsequent apoptosis in multiple cell types (Ahn and Zhang, data in preparation for publication). Because full-length AML1-ETO expression also induces growth arrest/apoptosis, and disruption of AML1-ETO and SON interaction alleviates this adverse effect on cell growth, it is likely that the interaction of AML1-ETO with SON inhibits or alters the normal function of SON. Although it has been reported that deletion of the NHR4 domain eliminates the ability of ETO to interact with N-CoR (27, 28) , these interactions were observed in yeast using Gal4-fused ETO fragments. In fact, Lutterbach et al. observed that the ETO fragment with NHR3/NHR4 deleted still interacted with full-length N-CoR in Cos-7 cell lysates (27) . Recently, Liu et al. also reported that a C-terminal truncation of AML1-ETO that removed NHR3/NHR4 domains did not affect N-CoR or SMRT binding in transfected Cos7 cell lysates (29) . We also demonstrated here that N-CoR binding is not disrupted when the NHR4 domain is deleted or mutated at C663 in mammalian cells. These observations from several groups indicate that N-CoR interaction is not significantly disrupted in mammalian cells when NHR4 is deleted. This is possibly due to other regions of ETO providing N-CoR binding sites. In contrast, NHR4 deletion or C663S mutation significantly disrupted ETO-SON interaction. Therefore, it is highly possible that disruption of AML1-ETO interaction with SON, rather than AML1-ETO interaction with N-CoR, contributes to progression of AML1-ETO-associated leukemia, although we still cannot totally exclude the possibility that the slight reduction in N-CoR recruitment to AML1-ETO, which is not detectable by immunoprecipitation and Western blot, also contributes to leukemogenesis.
Because AML1-ETO with the C663S mutation, which specifically disrupts the interaction with SON, is leukemogenic, and expression of the N-terminal fragment of SON (SON-140) that binds to AML1-ETO keeps cells proliferating in the presence of AML1-ETO, it is highly predictable that expression of AML1-ETO together with SON-140 would be leukemogenic in mice. However, when AML1-ETO expression exceeds the amount of SON-140, cells still undergo growth arrest (Fig. S5) , suggesting that the relative amount of AML1-ETO and SON-140 would be an important factor to consider for the mouse model of coexpression of AML1-ETO and SON-140. We are currently seeking a method to coexpress these two proteins at the right level in primary hematopoietic cells.
We confirmed that AML1-ETO is indeed localized in the nucleus in the t(8;21)-positive cell lines (data not shown) and patient samples (Fig. S6) . Therefore, cytoplasmic SON observed in t(8;21)-positive cell lines and t(8;21) AML patient samples does not interact with AML1-ETO and may help cells keep proliferating in the presence of AML1-ETO. As both Kasumi-1 and SKNO-1 cells have relatively low levels of AML1-ETO9a isoform expression (13) , and as the patient samples that we tested also contained full-length AML1-ETO as a dominant form (data not shown), dislocation of SON might be one of the common ''additional mutations'' for leukemogenesis of t(8;21)q (22, 22) -positive cells that express mainly full-length AML1-ETO. Although we observed cytoplasmic localization of SON in t(8;21)-positive patient samples, exogenous expression of AML1-ETO, AML1-ETO9a isoform, ETO, or ETO-C663S in HeLa cells did not cause cytoplasmic localization of SON (Fig. S7A) . In addition, when AML1-ETO and AML1-ETO9a isoform were coexpressed (Fig. S7B) , which was the case in t(8;21)-positive patients (13), SON was still localized as speckles within the nucleus (Fig. S7C) . These results suggest that AML1-ETO or its isoform do not directly cause cytoplasmic localization of SON. It is likely that expression of AML1-ETO and abnormal localization of SON are independent events that cooperate for leukemia development.
It is of interest to determine the exact localization of cytoplasmic SON. We performed experiments to determine whether cytoplasmic SON in t(8;21)-positive cells is localized in particular cytoplasmic organelles, such as the endoplasmic reticulum (ER), the Golgi, and lysosomes/endosomes. SON did not colocalize with any of these organelles (Fig. S8) , indicating that cytoplasmic SON is not present as a component of the ER, the Golgi, or lysosomes/endosomes, and the SON protein detected in the cytoplasm does not merely represent a degraded form of SON. Interestingly, costaining of SON with a Golgi marker, GM130, showed that although sequestered SON protein is not exactly colocalized with the Golgi, it is adjacent to the Golgi. We found that the N-terminal fragment of SON (1-140 aa) is sufficient to localize at the nuclear speckles (Fig. 5A). Therefore, it is possible that the SON protein detected in cytoplasm has mutations at the N-terminal region, or is an isoform that does not contain nuclear localization signals. Because SON contains potential RNA-binding motifs at its Cterminal end, it is likely that SON is associated with RNAs in the cytoplasm. The function of nuclear/cytoplasmic SON is currently under investigation. Taken together, our study demonstrates that the molecular events associated with disruption of normal function of NHR4 could be a secondary mutation that cooperates with AML1-ETO to promote leukemogenesis. Furthermore, we identified a NHR4-interacting partner SON, a protein with potential DNA-RNA dual binding ability, providing the a link between SON and a diseasecausing factor. The interaction between NHR4 of AML1-ETO and SON may be one of the factors generating inhibitory effects on leukemia development by blocking cell proliferation. Abnormalities of SON localization in blood cells from t(8;21) AML patients were first demonstrated in our study, which reveals a novel drug target for leukemia. Further studies to elucidate the biological function of SON may provide valuable insight into the control of cell transformation and cancer development.
Methods
Cell Lines and AML Patient Samples. Kasumi-1, SKNO-1, K562, U937, and U937T-AML1-ETO tet-inducible cell lines were grown in RPMI MEDIUM 1640, and 293T and HeLa cells in Dulbecco's modified Eagle's medium, supplemented with 10% (vol/vol) FBS. Blood samples were collected from patients with newly diagnosed AML at Aarhus University Hospital (Aarhus, Denmark). All sampling was performed as part of the diagnostic process and according to protocols approved by the ethical committee for the County of Aarhus.
Fetal Liver Cell Isolation, Retroviral Transduction, Transplantation, Hematological Analysis, and Flow Cytometry. Fetal liver cells were harvest from E14.5 mouse embryos (MF-1), infected with retroviruses containing MigR1 empty vector, MigR1-AE-⌬NHR4, or MigR1-AE-C663S and transplanted into the recipient MF-1 mice. Procedures were performed as described previously (12, 13) .
Transfection, Infection, and Nucleofection. Transfection of 293T and HeLa cell was performed using Polyfect (Qiagen) as described previously (30) . Infection of K562 and U937T cells was performed as described previously (31) . Nucleofection of K562 cells was performed according to the manufacturer's protocol (Amaxa). Negative control siRNA (catalog no. 4621) and SON siRNA (catalog no. 16708, siRNA ID no. 143161, 143162, 143163) were purchased from Ambion and transfected into cells using Lipofectamine 2000 (Invitrogen) for adherent cells, and nucleofection for suspension cells.
Yeast Two Hybrid Screening. Yeast two hybrid screening was performed by the TetR-based Two-hybrid system (Proteinlinks Inc.) to screen a cDNA library of the murine multipotential hematopoietic precursor cell line, EML (a gift from Dr. Schickwann Tsai, University of Utah, Salt Lake City, UT).
Production of SON Antibody. Polyclonal antibody was produced in rabbits for human SON a.a. 2090 -2107 (EEKVAKKSGGATIEELTE), and purified by affinity chromatography (Open Biosystems).
Further Details. Additional information about the experimental methods may be found in SI Methods.
